Napo Pharmaceuticals Presents Pediatric IF Study at ESPGHAN Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 24 2026
0mins
Should l Buy JAGX?
Jaguar Health family company Napo Pharmaceuticals announced the acceptance of two late breaking abstracts for the treatment of pediatric IF from MVID and SBS at the 58th Annual Meeting of ESPGHAN. These pediatric IF patients are receiving liquid oral crofelemer as an investigational drug under two separate investigator-initiated trials. One infant MVID IF patient is being treated with crofelemer as adjunctive therapy to parenteral support for more than 6 months and other pediatric patients with IF due to MVID and/or SBS received crofelemer adjunctive therapy for over 1 year together with reduced amounts of parenteral support. "We are pleased with these results for the safety and effectiveness of liquid oral crofelemer as adjunctive therapy to PS pediatric IF patients on life-sustaining PS. MVID is a congenital enteropathy and has a lethal natural history if not treated with life-sustaining and lifelong total parenteral nutrition with or without supplemental intravenous fluids. MVID is estimated to have a prevalence of approximately 200 patients, and to the best of our knowledge, crofelemer is being used to treat approximately 4% of the prevalent MVID patients, with the inclusion of additional MVID patients in an ongoing blinded study. Crofelemer has demonstrated reductions in parenteral support needs for IF patients with both MVID and SBS. Crofelemer has been well tolerated, and the pediatric IF patients are gaining weight and height, demonstrating reductions in their needs for PS, especially when adjusted for body weight. This is important because TPN is associated with significant comorbidities and reductions in PS needs are expected to improve clinical outcomes as well as quality of life measures for these pediatric IF patients," said Dr. Pravin Chaturvedi, Napo's CSO. Napo is continuing to enroll adult patients with IF due to SBS using the same formulation of crofelemer. This randomized double-blind placebo-controlled trial is being conducted at multiple sites in Germany and Italy. An investigational study in adult SBS-IF patients is also being partially supported by the company in the US.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JAGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JAGX
About JAGX
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jaguar Health Advances Towards Full FDA Approval of Crofelemer
- Clinical Trial Results: Jaguar Health announced the completion of its effectiveness trial for Crofelemer (Canalevia-CA1) in treating chemotherapy-induced diarrhea, revealing that dogs treated with Canalevia-CA1 achieved normal average daily stool after three days, indicating the drug's potential in canine diarrhea treatment.
- Positive Owner Feedback: At the study's conclusion, 83% of dog owners reported that Canalevia-CA1 was effective for their dog's diarrhea, with around 40% stating that their dog's diarrhea was completely resolved, showcasing significant efficacy and market demand for the drug.
- Comparative Analysis: In contrast, only 12.5% of owners whose dogs did not receive any treatment reported improvements, highlighting Canalevia-CA1's unique advantages in treating chemotherapy-induced diarrhea, which could lead to increased market share for the company.
- Future Plans: Jaguar intends to submit the complete trial data to support full regulatory approval for Crofelemer and seek scientific publication, demonstrating the company's strategic vision to expand treatment options for canine diarrhea, potentially driving future business growth.
See More
Jaguar Health Leverages AI for Crofelemer Treatment Advancement
- AI Technology Application: Jaguar Health plans to utilize artificial intelligence platforms to advance Crofelemer's application in treating intestinal failure (IF) in both adults and children, mining large datasets to identify links between genetics, histopathology, and clinical manifestations, thereby accelerating the development and FDA approval of new therapies.
- Orphan Disease Treatment: Crofelemer is used to relieve diarrhea symptoms in HIV/AIDS patients undergoing antiretroviral therapy, and currently, there are no alternative treatments for pediatric microvillus inclusion disease (MVID), highlighting the drug's significance for specific patient populations.
- Market Performance Recovery: Jaguar Health's stock price rose 5.69% to $0.39 at Monday's close, with premarket trading further increasing by 6.10% to $0.41, reflecting positive market expectations regarding its AI strategy and the potential of Crofelemer.
- Strategic Implications: By integrating AI technology with the development of Crofelemer, Jaguar Health not only enhances treatment efficacy but also potentially opens new market opportunities in the orphan disease sector, strengthening the company's competitive position in the biopharmaceutical industry.
See More
Jaguar Health Reports Q4 2025 Earnings Highlights
- Revenue Growth: Jaguar Health reported a net revenue of approximately $3.2 million for Q4 2025, reflecting a 5% increase from Q3 2025, although it represents an 8% decline compared to Q4 2024, indicating challenges in revenue stability.
- Strategic Partnership: The transformative out-license agreement with Future Pak for Mytesi provides $18 million upfront, with $16 million already received, which will support the development of its rare disease pipeline, enhancing Crofelemer's profitability.
- Clinical Advancements: The company is in late-stage clinical development for rare disease intestinal failure, with promising data showing a reduction in parenteral support needs by up to 37%, and aims to file a new drug application by 2027, targeting a market opportunity estimated at $8 billion.
- Market Challenges: Despite the partnership with Future Pak enhancing commercialization capabilities, prescription volume for Mytesi decreased by approximately 12.2% in Q4 2025 compared to the previous year, and the company faces regulatory approval challenges for new drug applications, which may impact future revenue growth.
See More
Jaguar Health Completes Study on Chemotherapy-Induced Diarrhea in Dogs
- Study Completion: Jaguar Health announced the completion of its effectiveness study on crofelemer delayed-release tablets for chemotherapy-induced diarrhea in dogs, with results expected to be submitted in Q2 2026, potentially paving the way for full drug approval.
- FDA Approval Renewal: The FDA has granted a fifth and final renewal of conditional approval for Canalevia-CA1 until December 21, 2026, underscoring the drug's significance in treating chemotherapy-induced diarrhea and addressing the market's need for effective solutions.
- Significant Clinical Results: The use of crofelemer in dogs receiving neratinib chemotherapy resulted in a 30% reduction in both the incidence and severity of diarrhea, providing strong support for the drug's clinical application and effectiveness.
- Large Market Potential: With approximately 90 million dogs in the U.S., over 11 million of which suffer from diarrhea annually, there is a pressing demand for effective treatment options, positioning Jaguar Health's product to fill this market gap.
See More
Jaguar Health Reports Q4 2025 Financial Results
- Revenue Decline: Jaguar Health reported Q4 2025 revenue of $3.2 million, an 8.6% year-over-year decrease, indicating significant market pressure and sales challenges that could impact future liquidity and investor confidence.
- Widening Net Loss: The net loss attributable to common shareholders increased to $53.6 million in 2025 from $38.5 million in 2024, reflecting a $15.1 million rise that highlights severe challenges in cost control and profitability, potentially raising shareholder concerns about the company's future.
- Prescription Volume Drop: Mytesi prescription volume decreased by approximately 3.7% in 2025 compared to 2024, with a 5.8% decline in Q4 2025 over Q3 2025, suggesting weak market demand that may affect future revenue growth and market share.
- Minimal License Revenue: The company recognized only $42,500 in license fees from a securities purchase agreement with a European partner in Q4 2025, indicating that revenues from non-prescription Neonorm products were negligible, which may limit the company's investment capacity in new product development.
See More
Jaguar Announces Extension of MVID Clinical Trial
- Clinical Trial Extension: Napo Pharmaceuticals announced the initiation of a single-blind extension phase for its MVID trial, supported by the FDA, aiming to improve clinical outcomes by reducing parenteral support (PS) requirements, which could significantly lower co-morbidity risks associated with MVID.
- Patient Participation: Currently, approximately 30% of MVID patients have completed the double-blind treatment phase, with clinical investigators supporting their participation in the single-blind extension phase to further assess the clinical benefits of crofelemer, enhancing treatment efficacy.
- Regulatory Pathway Exploration: Jaguar anticipates that this extension phase may facilitate obtaining Breakthrough Therapy designation from the FDA, potentially providing expedited regulatory pathways for new drug approval to address the urgent treatment needs of this ultrarare disease.
- Global Clinical Network: The clinical trial has sites in the US, Italy, and the UAE, having received approvals from the FDA, EMA, and respective health ministries, demonstrating Jaguar's commitment and capability to advance MVID treatment on a global scale.
See More
Jaguar Health Advances Towards Full FDA Approval of Crofelemer
- Clinical Trial Results: Jaguar Health announced the completion of its effectiveness trial for Crofelemer (Canalevia-CA1) in treating chemotherapy-induced diarrhea, revealing that dogs treated with Canalevia-CA1 achieved normal average daily stool after three days, indicating the drug's potential in canine diarrhea treatment.
- Positive Owner Feedback: At the study's conclusion, 83% of dog owners reported that Canalevia-CA1 was effective for their dog's diarrhea, with around 40% stating that their dog's diarrhea was completely resolved, showcasing significant efficacy and market demand for the drug.
- Comparative Analysis: In contrast, only 12.5% of owners whose dogs did not receive any treatment reported improvements, highlighting Canalevia-CA1's unique advantages in treating chemotherapy-induced diarrhea, which could lead to increased market share for the company.
- Future Plans: Jaguar intends to submit the complete trial data to support full regulatory approval for Crofelemer and seek scientific publication, demonstrating the company's strategic vision to expand treatment options for canine diarrhea, potentially driving future business growth.
See More
Jaguar Health Leverages AI for Crofelemer Treatment Advancement
- AI Technology Application: Jaguar Health plans to utilize artificial intelligence platforms to advance Crofelemer's application in treating intestinal failure (IF) in both adults and children, mining large datasets to identify links between genetics, histopathology, and clinical manifestations, thereby accelerating the development and FDA approval of new therapies.
- Orphan Disease Treatment: Crofelemer is used to relieve diarrhea symptoms in HIV/AIDS patients undergoing antiretroviral therapy, and currently, there are no alternative treatments for pediatric microvillus inclusion disease (MVID), highlighting the drug's significance for specific patient populations.
- Market Performance Recovery: Jaguar Health's stock price rose 5.69% to $0.39 at Monday's close, with premarket trading further increasing by 6.10% to $0.41, reflecting positive market expectations regarding its AI strategy and the potential of Crofelemer.
- Strategic Implications: By integrating AI technology with the development of Crofelemer, Jaguar Health not only enhances treatment efficacy but also potentially opens new market opportunities in the orphan disease sector, strengthening the company's competitive position in the biopharmaceutical industry.
See More
Jaguar Health Reports Q4 2025 Earnings Highlights
- Revenue Growth: Jaguar Health reported a net revenue of approximately $3.2 million for Q4 2025, reflecting a 5% increase from Q3 2025, although it represents an 8% decline compared to Q4 2024, indicating challenges in revenue stability.
- Strategic Partnership: The transformative out-license agreement with Future Pak for Mytesi provides $18 million upfront, with $16 million already received, which will support the development of its rare disease pipeline, enhancing Crofelemer's profitability.
- Clinical Advancements: The company is in late-stage clinical development for rare disease intestinal failure, with promising data showing a reduction in parenteral support needs by up to 37%, and aims to file a new drug application by 2027, targeting a market opportunity estimated at $8 billion.
- Market Challenges: Despite the partnership with Future Pak enhancing commercialization capabilities, prescription volume for Mytesi decreased by approximately 12.2% in Q4 2025 compared to the previous year, and the company faces regulatory approval challenges for new drug applications, which may impact future revenue growth.
See More
Jaguar Health Completes Study on Chemotherapy-Induced Diarrhea in Dogs
- Study Completion: Jaguar Health announced the completion of its effectiveness study on crofelemer delayed-release tablets for chemotherapy-induced diarrhea in dogs, with results expected to be submitted in Q2 2026, potentially paving the way for full drug approval.
- FDA Approval Renewal: The FDA has granted a fifth and final renewal of conditional approval for Canalevia-CA1 until December 21, 2026, underscoring the drug's significance in treating chemotherapy-induced diarrhea and addressing the market's need for effective solutions.
- Significant Clinical Results: The use of crofelemer in dogs receiving neratinib chemotherapy resulted in a 30% reduction in both the incidence and severity of diarrhea, providing strong support for the drug's clinical application and effectiveness.
- Large Market Potential: With approximately 90 million dogs in the U.S., over 11 million of which suffer from diarrhea annually, there is a pressing demand for effective treatment options, positioning Jaguar Health's product to fill this market gap.
See More
Jaguar Health Reports Q4 2025 Financial Results
- Revenue Decline: Jaguar Health reported Q4 2025 revenue of $3.2 million, an 8.6% year-over-year decrease, indicating significant market pressure and sales challenges that could impact future liquidity and investor confidence.
- Widening Net Loss: The net loss attributable to common shareholders increased to $53.6 million in 2025 from $38.5 million in 2024, reflecting a $15.1 million rise that highlights severe challenges in cost control and profitability, potentially raising shareholder concerns about the company's future.
- Prescription Volume Drop: Mytesi prescription volume decreased by approximately 3.7% in 2025 compared to 2024, with a 5.8% decline in Q4 2025 over Q3 2025, suggesting weak market demand that may affect future revenue growth and market share.
- Minimal License Revenue: The company recognized only $42,500 in license fees from a securities purchase agreement with a European partner in Q4 2025, indicating that revenues from non-prescription Neonorm products were negligible, which may limit the company's investment capacity in new product development.
See More
Jaguar Announces Extension of MVID Clinical Trial
- Clinical Trial Extension: Napo Pharmaceuticals announced the initiation of a single-blind extension phase for its MVID trial, supported by the FDA, aiming to improve clinical outcomes by reducing parenteral support (PS) requirements, which could significantly lower co-morbidity risks associated with MVID.
- Patient Participation: Currently, approximately 30% of MVID patients have completed the double-blind treatment phase, with clinical investigators supporting their participation in the single-blind extension phase to further assess the clinical benefits of crofelemer, enhancing treatment efficacy.
- Regulatory Pathway Exploration: Jaguar anticipates that this extension phase may facilitate obtaining Breakthrough Therapy designation from the FDA, potentially providing expedited regulatory pathways for new drug approval to address the urgent treatment needs of this ultrarare disease.
- Global Clinical Network: The clinical trial has sites in the US, Italy, and the UAE, having received approvals from the FDA, EMA, and respective health ministries, demonstrating Jaguar's commitment and capability to advance MVID treatment on a global scale.
See More
